SHARE:  

WESTCHESTER COUNTY LIFE SCIENCES UPDATE

Featuring news, events and industry trends

IN THIS NEWSLETTER


  • MediSprout Reaches Important Milestone, Evolves Into a Hybrid Practice Management Solution
  • Can't Miss Webinar Outlining New Rules and Requirements for Ventures Applying for SBIR/STTR Funding - Today at 2 PM
  • HHS Announces New Details of Partnership with Regeneron to Develop Life-Saving Monoclonal Antibodies
  • Join the Westchester County Biosciences Accelerator Community: Apply Today!
  • Upcoming Events & More

MediSprout Reaches Important Milestone, Evolves Into a Hybrid Practice Management Solution


With the push of its latest software update, Valhalla’s MediSprout became a full-scale hybrid practice management solution, targeting small and startup behavioral and mental health practices. In the new HIPAA-compliant MediSprout platform, providers now have technology that supports hundreds of practice-wide functions such as patient scheduling and intake for video or in-person visits, automated admin and nonclinical tasks, secure provider notetaking and storage, and features that support the industry's move to patient-controlled records and patient-centric care. 


Established as a telehealth solution in 2019, MediSprout uses technology and data to elevate the healthcare experience for patients, providers, and organizations. It was founded by Samant Virk, MD.


Read more

Can't Miss Webinar Outlining New Rules and Requirements for Ventures Applying for SBIR/STTR Funding -

Today at 2PM


Following reauthorization by Congress of the SBIR/STTR Programs in 2022, there are new rules companies should familiarize themselves with concerning required disclosures of foreign affiliations or relationships with foreign countries. In addition to mandating disclosures prior to receiving SBIR awards, companies must also regularly update NIH following any changes to a disclosure. Join BIO for a comprehensive discussion today, September 19, at 2:00 PM on how to effectively navigate these new rules as you apply for SBIR awards.


"New SBIR Foreign Disclosure Requirements: How Does it Impact Your Company?" will be co-hosted by the National Institutes of Health (NIH) Seed Office.


Speakers:

  • Stephanie Fertig, Program Lead, Health and Human Services Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR), National Institutes of Health (NIH)
  • Patricia Valdez, Chief Extramural Research Integrity Officer, Office of Extramural Research, National Institutes of Health (NIH)


Register

HHS Announces New Details on Partnership with Regeneron to Develop Life-Saving Monoclonal Antibodies


The U.S. Department of Health and Human Services (HHS) announced new details of its agreement with Regeneron to extend its public-private partnership to develop life-saving monoclonal antibodies as part of Project NextGen, which centers on enhancing our preparedness for COVID-19 strains and variants.


The HHS is committed to lowering drug costs for all Americans. As part of that commitment, HHS and Regeneron announced an extension of their long-standing partnership to develop life-saving monoclonal antibodies. That modification to Regeneron’s contract with the Administration for Strategic Preparedness and Response’s (ASPR’s) Biomedical Advanced Research and Development Authority, is valued at $326 million and supports the advanced development of a next generation monoclonal antibody for COVID-19 prevention under HHS’s Project NextGen.


This agreement included a clause where Regeneron committed that if a new product is commercialized, its list price in the United States will be equal to or less than its retail price in comparable markets globally. Inclusion of this clause is the result of HHS’s and Regeneron’s shared interest in ensuring enduring and equitable access to therapeutics developed under public-private partnerships for all Americans. 


Read more

Join the Westchester County Biosciences Accelerator Community: Apply Today!


Life science ventures at any stage of development are still able to apply for the 2024 cohort of the Westchester County Biosciences Accelerator! Join a community of nearly 50 founders and expert mentors that has raised over $15 million in funding. 


Apply (Deadline: October 24)


Upcoming Information Sessions

Learn more about the program, meet alumni and hear what you stand to gain from becoming a 2024 venture at an upcoming information session: 


2024 Program Info Sessions

Date: September 20

Time: 12:00 PM

Register


Date: September 26

Time: 12:00 PM

Register


Strengthening Your Application Workshops

Date: October 4

Time: 12:00 PM

Register


If you have questions and would like to learn more about WCBA, contact Doris Alcivar, Assistant Program Manager, WCBA at doris@firstxfounder.com.  

UPCOMING EVENTS & MORE

Biosciences Sales & Business Development Masterclass

Presented by ELabNYC & FirstxFounder


Join this online Biosciences Sales & Business Development Masterclass, September 2728, to gain invaluable insights and strategies for success. The Masterclass is ideal for ventures seeking growth and profitability strategies to sell to customers, corporate partners, or recruiting new team members.


Register


Have good news to share with

Westchester’s life sciences ecosystem?


Please let us know.

Email lifesciences@westchestergov.com.



If you would like to continue receiving this weekly newsletter,
please sign up below. If you would like to contact us directly, click the Contact Us link.

SIGN UP
CONTACT US
Facebook  Twitter  Instagram  Linkedin